Document is current
Any future updates will be listed below
-
Authors
Barrot-de la Puente, Joan
Lopez Arpí, Carlos
Ramon Granes, Maria
Escribà Planes, Marta
Fernandez-Camins, Berta
Vlacho, Bogdan
Franch-Nadal, Josep
-
Funding
Funding for this research was provided by:
Red de Grupos de Estudio de la Diabetes en Atención Primaria de la Salud – RedGDPS
- License Information
-
More Information
Article History
Received: 2 July 2025
Accepted: 11 November 2025
First Online: 24 November 2025
Declarations
:
: The study was conducted according to the guidelines of the Declaration of Helsink,1 October 2024. The IDIAP Jordi Gol Ethics Committee approved the study, protocol approval number 23/030-P, on 29/03/2023. The need for informed consent was waived by the Clinical Research Ethics Committee of IDIAP Jordi Gol, as the study involved retrospective analysis of anonymized data. This waiver complies with the national regulations outlined in the Biomedical Research Law 14/2007 (Spain), which allows the use of health data for research purposes without informed consent when data are anonymized and obtaining consent is impracticable.Not applicable.
: Not applicable.
: J. B-P has received speaking fees from Boehringer Ingelheim. Astra-Zeneca.Lilly. MSD. Novo Nordisk. Sanofi. J. F-N has received advisory and or speaking fees from Astra-Zeneca. Ascensia, Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, Novo Nordisk and Sanofi; he has received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, Novo Nordisk, Sanofi and Boehringer Ingelheim. M. R-G; B.F-C; M.E-P; B.V and J.L-A declare no conflict of interest for this analysis.
